Community Mental Health Journal

, Volume 45, Issue 4, pp 251–254 | Cite as

Metabolic Consequences of Using Low-Dose Quetiapine for Insomnia in Psychiatric Patients

  • Marshall E. Cates
  • Cherry W. Jackson
  • Jacqueline M. Feldman
  • Amanda E. Stimmel
  • Thomas W. Woolley
Original Paper

Abstract

Quetiapine is frequently prescribed for insomnia that is comorbid with psychiatric disorders, but there has been no documentation of metabolic adverse effects associated with this practice. The objective of this study was to document changes in weight, body mass index, and waist circumference that occurred when low-dose quetiapine was used at bedtime for insomnia. The study was a retrospective chart review conducted at a community mental health center. Patients were non-elderly (19–65 years old) psychiatric patients who received quetiapine at ≤200 mg at bedtime for the explicit indication of insomnia. Forty-three patients were included in the study. Weight and BMI increased by an average of 4.9 lb. (P = 0.037) and 0.8 points (P = 0.048), respectively. Males experienced statistically significant increases in weight and BMI, and Caucasians experienced a statistically significant increase in BMI. There were no significant differences between baseline and endpoint metabolic parameters when examined by baseline BMI, age category, psychiatric diagnosis, or concomitant psychotropic medication. Despite the low doses typically used when quetiapine is prescribed for insomnia, metabolic adverse effects can occur and should be considered in the overall benefit to risk analysis.

Keywords

Quetiapine Insomnia Psychiatry Weight gain Body mass index 

References

  1. Adityanjee, S. S. C., & Schulz, S. C. (2002). Clinical use of quetiapine in disease states other than schizophrenia. The Journal of Clinical Psychiatry, 63(suppl 13), 32–38.PubMedGoogle Scholar
  2. Aichhorn, W., Whitworth, A. B., Weiss, E. M., & Marksteiner, J. (2006). Second generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Safety, 29(7), 587–598. doi: 10.2165/00002018-200629070-00004.PubMedCrossRefGoogle Scholar
  3. Becker, P. M. (2006). Treatment of sleep dysfunction and psychiatric disorders. Current Treatment Options in Neurology, 8(5), 367–375. doi: 10.1007/s11940-006-0026-6.PubMedCrossRefGoogle Scholar
  4. Bhat, A., Shafi, F., & Solh, A. A. E. (2008). Pharmacotherapy of insomnia. Expert Opinion on Pharmacotherapy, 9(3), 351–362. doi: 10.1517/14656566.9.3.351.PubMedCrossRefGoogle Scholar
  5. Brecher, M., Leong, R. W., Stening, G., Osterling-Koskinen, L., & Jones, A. M. (2007). Quetiapine and long-term weight change: A comprehensive data review of patients with schizophrenia. The Journal of Clinical Psychiatry, 68(4), 597–603.PubMedCrossRefGoogle Scholar
  6. Cohrs, S., Rodenbeck, A., Guan, Z., Pohlmann, K., Jordan, W., Meier, A., et al. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology, 174(3), 421–429.PubMedGoogle Scholar
  7. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. (2004). Diabetes Care, 27(2), 596–601.Google Scholar
  8. Newcomer, J. W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19(suppl 1), 1–93. doi: 10.2165/00023210-200519001-00001.PubMedGoogle Scholar
  9. Passarella, S., & Duong, M. T. (2008). Diagnosis and treatment of insomnia. American Journal of Health-System Pharmacy, 65(10), 927–934. doi: 10.2146/ajhp060640.PubMedCrossRefGoogle Scholar
  10. Philip, N. S., Mello, K., Carpenter, L. L., Tyrka, A. R., & Price, L. H. (2008). Patterns of quetiapine use in psychiatric inpatients: An examination of off-label use. Annals of Clinical Psychiatry, 20(1), 15–20. doi: 10.1080/10401230701866870.PubMedCrossRefGoogle Scholar
  11. Todder, D., Caliskan, S., & Baune, B. T. (2006). Night locomotor activity and quality of sleep in quetiapine-treated patients with depression. Journal of Clinical Psychopharmacology, 26(6), 638–642. doi: 10.1097/01.jcp.0000239798.59943.77.PubMedCrossRefGoogle Scholar
  12. Wiegand, M. H., Landry, F., Brückner, T., Pohl, C., Veselý, Z., & Jahn, T. (2008). Quetiapine in primary insomnia: A pilot study. Psychopharmacology, 196(2), 337–338. doi: 10.1007/s00213-007-0968-8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Marshall E. Cates
    • 1
  • Cherry W. Jackson
    • 2
  • Jacqueline M. Feldman
    • 3
  • Amanda E. Stimmel
    • 4
  • Thomas W. Woolley
    • 5
  1. 1.Samford University McWhorter School of PharmacyBirminghamUSA
  2. 2.Auburn University Harrison School of PharmacyAuburnUSA
  3. 3.Division of Public PsychiatryUniversity of Alabama at Birmingham School of MedicineBirminghamUSA
  4. 4.Walgreen Co.HartselleUSA
  5. 5.Samford University Brock School of BusinessBirminghamUSA

Personalised recommendations